Navigation Links
Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment
Date:11/3/2008

SAN FRANCISCO (November 3, 2008) New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection. Tibotec will present findings from three TMC435 studies, including a late-breaker poster on the proof-of-principle phase IIa trial, OPERA-1 (TMC435-C201), at the American Association for the Study of Liver Disease's (AASLD) Liver Meeting 2008 in San Francisco.

The current standard of care treatment for HCV infection, pegylated interferon (Peg-IFN) combined with ribavirin (RBV), is effective in 30 to 50 percent of patients infected with chronic genotype 1 HCV infection, the most common type in the United States. The development of new therapies and strategies for treating HCV, particularly the introduction of direct antivirals, may offer patients a new option with shorter treatment duration.

TMC435 Phase IIa Study Results

In interim findings from the first 28 days of treatment for the first cohort of fifty (50) treatment nave HCV+, genotype 1, patients (once daily dose of 25 mg or 75 mg TMC435 versus placebo), both doses showed dose-dependent antiviral activity. TMC435 was administered in combination with PegIFNα-2a/RBV (triple therapy) for 28 days or as monotherapy for seven days and, thereafter, in combination with PegIFNα-2a/RBV (triple therapy) for three weeks. There were neither serious adverse events, nor grade 3 or 4 adverse events, related to TMC435 or any safety-related treatment discontinuations during this 28 day treatment period.

The most common adverse events associated with TMC435 were nausea, diarrhea, and headache. There were no clinically relevant changes in laboratory parameters, ECGs, or vital signs. Steady-state plasma trough levels of TMC435 25 mg and 75 mg represented ~10 and >30-fold excess above the HCV replicon EC50 value, respectively.

Mean
'/>"/>

Contact: Julian Teixeira
julian.teixeira@zenogroup.com
202-965-7808
Zeno Group
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE
2. Updated GOLD report presents new understandings in diagnosis, treatment and prevention of COPD
3. The Art Of Maternity(TM) at Destination Maternity(R) Presents A Sacred Passage Into Motherhood; the Art of Belly Masking to Belly Casting
4. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
5. VNUS Medical Technologies Presents at William Blair Small-Cap Growth Stock Conference
6. NARSAD - Worlds Leading Mental Health Research Charity - Presents 19th Annual New York Mental Health Symposium, Oct. 19th & 20th
7. Retirement Living TV Presents Sex, Drugs and Rock N Roll
8. AviaraDx Presents at 2007 BIOCOM Investor Conference
9. NARSAD - the Worlds Leading Mental Health Research Charity - Presents 2007 Prizes for Outstanding Psychiatric Research at New York Gala, October 19th
10. California Science Center Science Matters Speakers Program Presents The Science and Ethics of Fear
11. Borgata Heart & Soul Foundation Presents Third Annual Women in Wine Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Care Communications, Inc., (CARE) a national health care ... Elite Award for “Recruitment, Selection and Orientation” from the ... awards presented as part of “Chicago’s 101 ... awards competition. This marks the seventh consecutive year Care ... CARE has also been chosen as a national winner ...
(Date:7/31/2014)... 31, 2014 Daily Gossip reveals in its ... sufferers discover some breakthrough weight loss tips. , The ... and recommendations are very simple to implement. Users don’t have ... with no need to start counting calories. , The ... in fact created a 12 weeks weight loss program to ...
(Date:7/31/2014)... In its latest blog post, Best ... having family close by during a stay in rehab can ... is successful, is looking at 10 tips to help drug ... recovery is a lifelong process, and one that former addicts ... without compromise,” commented Best Drug Rehabilitation’s CEO Per Wickstrom ...
(Date:7/31/2014)... 31, 2014 The study, The ... in Medicare episode of care payments for four clinical ... major joint replacements (hips and knees). Using the ... Payments for Care Improvement program, the study examines these ... regions in the country. , “Our study reaffirms that, ...
(Date:7/30/2014)... 30, 2014 The Mesothelioma ... Penn's Abramson Cancer Center, will host a regional ... experts in the field of mesothelioma. September 26 marks ... is open to the public, and specifically aimed at ... who have been exposed to asbestos. , The conference ...
Breaking Medicine News(10 mins):Health News:Care Communications, Inc. Named an Elite Award Winner Among Top Chicago Employers 2Health News:New Best Drug Rehabilitation Blog Posts Looks at 10 Tips for Coping After Drug or Alcohol Rehab 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 3Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 2Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 3
... in five Americans,suffers from the pain of arthritis. The ... the year 2030, 67 million people in the,U.S. will ... million.,Arthritis can be a painful, life-impacting condition, but its ... such as walking, is crucial in preventing and,managing the ...
... Press announces the,release of a new book -- ... to help older people understand and proactively address ... Dr. Heather D.,Hadjistavropoulos and their contributors, this softcover ... and,simple instructions for managing persistent pain., "With ...
... More, a,national non-profit dedicated to improving the lives ... season. Invisimomibility is a,chronic, pervasive condition in which ... inability to successfully fulfill one,s,caregiving, civic and paid ... and economic risk., For decades, the unpaid ...
... 25, 2008) -- Heart failure patients at NewYork-Presbyterian Hospital/Columbia ... implanted with the HeartMate II LVAS (Left Ventricular Assist ... hearts pump blood -- that has now received approval ... use as bridge to transplantation. As part of clinical ...
... WebMD Health Corp. (Nasdaq:,WBMD) and HLTH Corporation (Nasdaq: ... scheduled to participate at the Third Annual Needham & ... 2008 at 8:00 am ET., Investors, analysts and ... audio broadcast of the presentation over the Internet. The ...
... in,Brachioplasty (arm lift) techniques will be discussed by leading ... Aesthetic Plastic Surgery,(ASAPS) being held at the San Diego ... Arm: A Treatment Algorithm" will be moderated by,Daniel Morello, ... discuss,traditional Brachioplasty; Felmont Eaves, MD, who will discuss the,procedure ...
Cached Medicine News:Health News:GET UP AND MOVE! May is Arthritis Awareness Month - The Perfect Time to Learn the Importance of Staying Active 2Health News:New Book Helps Older Adults Manage Chronic Pain 2Health News:Mothers & More Fights to End Invisimomibility 2Health News:FDA approves HeartMate II mechanical heart pump for heart-failure patients 2Health News:Current Trends in Arm Lift Surgery 2Health News:Current Trends in Arm Lift Surgery 3
(Date:7/31/2014)... July 31, 2014   , 2014 Second Quarter ... prior year , Overall organic growth was 4% for same ... products; Bausch + Lomb grew 12% , 2014 Second ... 43% , 2014 Second Quarter GAAP Operating Cash Flow ... , Highlights of the Second Quarter , Launched 17 new ...
(Date:7/31/2014)... PARK, N.C. , July 31, 2014 ... Miami facilities to meet the clinical trial ... .  The newly expanded facility will continue to ... consolidation of shipments to and from the region, and ... its newest location, Marken will combine its office and ...
(Date:7/31/2014)... , July 31, 2014 Auxilium ... a specialty biopharmaceutical company, today announced that the ... payment from its partner Asahi Kasei Pharma Corporation ... the successful submission of a regulatory application to ... for XIAFLEX ® (collagenase clostridium histolyticum) for ...
Breaking Medicine Technology:Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 2Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 3Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 4Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 5Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 6Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 7Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 8Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 9Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 10Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 11Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 12Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 13Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 14Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 15Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 16Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 17Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 18Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 19Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 20Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 21Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 22Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 23Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 24Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 25Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 26Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 27Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 28Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 29Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 30Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 31Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 32Marken Expands Miami Regional Logistics Center 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 3Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 4
... , BUDAPEST, Hungary , ... Pfizer Globally Licenses ChemAxon,s Platform For Markush Structure,Searching And Enumeration ... of cheminformatics software for the life,sciences industry has entered into ... functionality for global,development and deployment within Pfizer,s global R&D facilities. ...
... , , , ... The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) ... sclerosis (MS). In clinical trials, patients treated with Ampyra had ... (placebo). This is the first drug approved for this use. ...
Cached Medicine Technology:FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: